Intelligence Feed event · Macro · 2026-09-24

    HUTCHMED and AstraZeneca present Phase III lung cancer data at ESMO 2026

    Question

    HUTCHMED and AstraZeneca present Phase III lung cancer data at ESMO 2026

    Direct answer

    HUTCHMED announced that clinical data from two pivotal Phase III trials evaluating savolitinib in combination with AstraZeneca's Tagrisso (osimertinib) will be presented at the ESMO Congress 2026 in Madrid. The global SAFFRON trial and the China-based SANOVO trial both yielded statistically significant and clinically meaningful efficacy metrics in patients with EGFR-mutated, MET-driven non-small cell lung cancer (NSCLC), paving the way for joint regulatory submissions.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-24
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “HUTCHMED and AstraZeneca present Phase III lung cancer data at ESMO 2026”, revision 1, evidence through 2026-09-24. https://marketontology.com/market-events/2026-09-24/hutchmed-and-astrazeneca-present-phase-iii-lung-cancer-data-at-esmo-2026-dbb7ea

    MACRO
    HUTCHMED and AstraZeneca present Phase III lung cancer data at ESMO 2026
    HUTCHMED announced that clinical data from two pivotal Phase III trials evaluating savolitinib in combination with AstraZeneca's Tagrisso (osimertinib) will be presented at the ESMO Congress 2026 in Madrid. The global SAFFRON trial and the China-based SANOVO trial both yielded statistically significant and clinically meaningful efficacy metrics in patients with EGFR-mutated, MET-driven non-small cell lung cancer (NSCLC), paving the way for joint regulatory submissions.
    HCMAZN
    Impact
    62
    SEP 24
    SIG
    86%
    HCMAZN
    HUTCHMED and AstraZeneca present Phase III lung cancer data at ESMO 2026
    HUTCHMED announced that clinical data from two pivotal Phase III trials evaluating savolitinib in combination with AstraZeneca's Tagrisso (osimertinib) will be presented at the ESMO Congress 2026 in Madrid. The global SAFFRON trial and the China-based SANOVO trial both yielded statistically significant and clinically meaningful efficacy metrics in patients with EGFR-mutated, MET-driven non-small cell lung cancer (NSCLC), paving the way for joint regulatory submissions.
    → Positive Phase III SAFFRON readouts support regulatory filing for savolitinib combination therapy, expanding AstraZeneca and HUTCHMED oncology revenue streams.
    Impact
    HUTCHMED announced that clinical data from two pivotal Phase III trials evaluating savolitinib in combination with AstraZeneca's Tagrisso (osimertinib) will be presented at the ESMO Congress 2026 in Madrid. The global SAFFRON trial and the China-based SANOVO trial both yielded statistically significant and clinically meaningful efficacy metrics in patients with EGFR-mutated, MET-driven non-small cell lung cancer (NSCLC), paving the way for joint regulatory submissions.
    Affected
    HCMAZN
    Transmission
    Positive Phase III SAFFRON readouts support regulatory filing for savolitinib combination therapy, expanding AstraZeneca and HUTCHMED oncology revenue streams.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    HCMclinical pipeline validation and milestone royalty visibilityUp1-5dPhase III SAFFRON and SANOVO studies demonstrate statistically significant results in NSCLC.
    AZNoncology franchise lifecycle extension via osimertinib combination label expansionUp1-4wSavolitinib combined with osimertinib shows positive Phase III results in partnered lung cancer studies.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    HCMUpagreed13.90 2026-09-24+0.29%+4.82%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month